Working directories
1 | i=/media/ht/ht_5T/Work/Projects/Other_Projects/Coronavirus_Project/Ref/Vaccine/Vaccine_20210117.pdf |
1 | i=/media/ht/ht_5T/Database/Virus/Herpesvirus/Herpesviridae; pcmanfm -n ${i}; cd ${i} |
BLAST
display1 | ################################################################## |
1 | Subject=/media/ht/ht_5T/Work/Funding/2017_重大专项/Management/Administration/09_02_63_HEV/Seq/HEV_25.fasta |
1 | install.packages(c("boot", "broom", "cachem", "cli", "cluster", "crayon", "crul", "data.table", "dbplyr", "deldir", "dotCall64", "dplyr", "gert", "ks", "lifecycle", "MASS", "mgcv", "mime", "nlme", "pillar", "pkgKitten", "promises", "qpcR", "rappdirs", "RcppArmadillo", "rgdal", "rgl", "rJava", "rmarkdown", "segmented", "sf", "SparseM", "spatstat.data", "spdep", "testthat", "usethis", "waldo", "xfun", "XLConnect")) |
ggtree
installation1 | if (!requireNamespace("BiocManager", quietly = TRUE)) |
1 | i=/media/ht/ht06/DB/SRA/Results/Essential/Extracted |
1 | i=/media/ht/ht_5T/Work/Funding/2021_十四五/第四批12个社会发展领域2021年度项目申报指南征求意见/十四五指南_Sum.pdf; setsid okular ${i} |
以上教程非常有用。
1 | i=/media/ht/ht_5T/Work/Projects/Herpesvirus_Project/EBV_CMV_Detect/20210219/EBV_B95-8_V01555.2.gb |
Keyword
Human herpesvirus 4
“Human gammaherpesvirus 4”[Organism] OR Human herpesvirus 4[All Fields]
1 | i=/media/ht/ht_5T/Database/Virus/Herpesvirus/EBV |
HHV4.summary
HHV4.gb
HHV4.fasta
Herpesviridae
“Herpesviridae”[Organism] OR Herpesviridae[All Fields]
1 | i=/media/ht/ht_5T/Work/Projects/Phage |
1 | i=/media/ht/ht_5T/Work/Projects/NFE/B95-8/Ref; pcmanfm -n ${i}; cd ${i} |
1 | i=/media/ht/ht_5T/Work/Projects/Herpesvirus_Project/EBV_CMV_Detect/20210219; pcmanfm -n ${i}; cd ${i} |
1 | i=ftp://ht@192.168.1.8:2121/BaiduNetdisk/resources |
1 | i=/media/ht/ht_5T/Work/Projects/Phage |
Bacteriophage presentation
1 | i=/media/ht/ht_5T/Work/Projects/Phage |
1 | i='/media/ht/ht_5T/Work/Projects/Phage/Summary'; cd ${i} |
Bacteriophage
1 | i=/media/ht/ht_5T/Work/Projects/Phage/README.md |
1 | i='/media/ht/ht_5T/Work/Projects/Phage/Materials' |
1 | i=/media/ht/ht_5T/Work/Projects/Phage/Patents |
Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning “to eat” or “to develop at the expense of”) are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
1 | i=/media/ht/ht_5T/Work/Projects/NFE/Summary/NFE2_Sum_Large.pdf |
1 | Site=ftp://ht@192.168.1.${i}:2121/DCIM; pcmanfm -n ${Site} # DCIM/Camera Directory |
1 | Site=ftp://ht@192.168.1.${i}:2121/Download; pcmanfm -n ${Site} # Download directory |
1 | Site=ftp://ht@192.168.1.${i}:2121/BaiduNetdisk; pcmanfm -n ${Site} # 百度网盘 |
1 | Site=ftp://ht@192.168.1.${i}:2121/Android/data/com.tencent.mm/MicroMsg/Download; pcmanfm -n ${Site} # WeChat/Weixin |
1 | Site=ftp://ht@192.168.1.${i}:2121/Android/data/com.tencent.mobileqq/Tencent/QQfile_recv; pcmanfm -n ${Site} ## Mobile QQ |
1 | Site=ftp://ht@192.168.1.${i}:2121/Documents/Study/COVID-19; pcmanfm -n ${Site} # COVID-19 |
1 | Site=ftp://ht@192.168.1.${i}:2121/Documents/Study/; pcmanfm -n ${Site} # Study |
1 | Site=ftp://ht@192.168.1.${i}:2121/Documents/markor/; pcmanfm -n ${Site} # Markor |
1 | mkdir `Date`;cd `Date`; pcmanfm -n |
1 | for i in 'https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_global.csv https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_deaths_global.csv https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_recovered_global.csv https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_US.csv https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_deaths_US.csv'; do wget ${i}; done |
The GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) is a global health partnership of public and private sector organizations dedicated to “immunisation for all”. It provides a unique opportunity for a wide-range of partners to build consensus around policies, strategies, and priorities and to recommend responsibility of implementation to the partner with the most experience and insight in the area. GAVI has developed innovative approaches to international health and development.
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a global initiative aimed at equitable access to COVID-19 vaccines led by the Global Alliance for Vaccines and Immunization, the World Health Organization, the Coalition for Epidemic Preparedness Innovations, and others.
COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched in April by the World Health Organization (WHO), the European Commission and France in response to this pandemic. Bringing together governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropy, with the aim of providing innovative and equitable access to COVID-19 diagnostics, treatments and vaccines. The COVAX pillar is focussed on the latter. It is the only truly global solution to this pandemic because it is the only effort to ensure that people in all corners of the world will get access to COVID-19 vaccines once they are available, regardless of their wealth.
1 | i=/media/ht/ht_5T/Bioinformatics/Bioinfo-Softs/NCBI/Datasets |
Publication downloaded from URL as below
1 | i=/media/ht/ht_5T/Bioinformatics/Bioinfo-Softs/NGS_Softs/Kaiju |
1 | i=https://az792536.vo.msecnd.net/vms/VMBuild_20190311/VirtualBox/MSEdge/MSEdge.Win10.VirtualBox.zip |
1 | # |
1 | i=/run/user/1000/gvfs/ftp:host=192.168.1.8,port=2121,user=ht/Download/ |
Priority and coverage of vaccine
tacrolimus, cyclosporine, mycophenolate, azathioprine, sirolimus
Other names: Epinephrine, adrenaline, adrenalin
Adrenaline, also known as epinephrine, is a hormone and medication which is involved in regulating visceral functions (e.g., respiration).. Adrenaline is normally produced both by the adrenal glands and by a small number of neurons in the medulla oblongata.
Generic Name: epinephrine injection (EP i NEF rin)
Brand Name: Adrenalin, Auvi-Q, Epinephrinesnap-EMS, Epinephrinesnap-V, EpiPen 2-Pak, EpiPen JR 2-Pak, EPIsnap, Symjepi
EpiPen 2-Pak is used to treat severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs, and other allergens.
Epinephrine auto-injectors may be kept on hand for self-injection by a person with a history of severe allergic reaction.
Epinephrine is also used to treat exercise-induced anaphylaxis, or to treat low blood pressure that is caused by septic shock.
EpiPen 2-Pak may also be used for purposes not listed in this medication guide.
The trial began on July 27, 2020, and enrolled 30,420 adult volunteers at clinical research sites across the United States. Volunteers were randomly assigned 1:1 to receive either two 100 microgram (mcg) doses of the investigational vaccine or two shots of saline placebo 28 days apart. The average age of volunteers is 51 years. Approximately 47% are female, 25% are 65 years or older and 17% are under the age of 65 with medical conditions placing them at higher risk for severe COVID-19. Approximately 79% of participants are white, 10% are Black or African American, 5% are Asian, 0.8% are American Indian or Alaska Native, 0.2% are Native Hawaiian or Other Pacific Islander, 2% are multiracial, and 21% (of any race) are Hispanic or Latino.
From the start of the trial through Nov. 25, 2020, investigators recorded 196 cases of symptomatic COVID-19 occurring among participants at least 14 days after they received their second shot. One hundred and eighty-five cases (30 of which were classified as severe COVID-19) occurred in the placebo group and 11 cases (0 of which were classified as severe COVID-19) occurred in the group receiving mRNA-1273. The incidence of symptomatic COVID-19 was 94.1% lower in those participants who received mRNA-1273 as compared to those receiving placebo.
Investigators observed 236 cases of symptomatic COVID-19 among participants at least 14 days after they received their first shot, with 225 cases in the placebo group and 11 cases in the group receiving mRNA-1273. The vaccine efficacy was 95.2% for this secondary analysis.
1 | i=/media/ht/ht_5T/Work/Projects/NFE/Publication/Draft/Rev_2 |
1 | i=/media/ht/ht_5T/Bioinformatics/软件使用说明_电影版/Not_Classified |
1 | i=/media/ht/ht_5T/Work/Funding/2017_重大专项/Management/Administration/09_02_63_HEV/CNN |
tag:
缺失模块。
1、请确保node版本大于6.2
2、在博客根目录(注意不是yilia根目录)执行以下命令:
npm i hexo-generator-json-content --save
3、在根目录_config.yml里添加配置:
jsonContent: meta: false pages: false posts: title: true date: true path: true text: false raw: false content: false slug: false updated: false comments: false link: false permalink: false excerpt: false categories: false tags: true